BCL2 and B-cell chronic lymphocytic leukemia: In 2016, venetoclax (ABT-199) was the first agent targeting BCL-2 to be approved by the US FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) harboring 17p deletion.